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Sarah Wild1*, Janet Hanley2, Stephanie Lewis1, John McKnight3,4, Lucy McCloughan1, Paul Padfield5,
Mary Paterson1, Hilary Pinnock1 and Brian McKinstry1*Abstract
Background: Diabetes prevalence is increasing and current methods of management are unsustainable. Effective
approaches to supporting self-management are required. The aim of this randomized controlled trial is to establish
whether supported telemetric monitoring of glycemic control and blood pressure results in reductions in
glycosylated hemoglobin (HbA1c; the primary outcome of a measure of long-term glycemic control) and secondary
outcomes of blood pressure and weight among people with poorly controlled diabetes compared to a control
group receiving usual care.
Methods/Design: Design: multi-center, randomized controlled trial with embedded qualitative study.
Setting: primary care in Lothian, Kent, Glasgow and Borders regions in the UK.
Participants: people with type 2 diabetes and confirmed HbA1c >7.5% (58 mmol/mol).
Intervention/comparison: randomization to intervention or control groups will be performed by the Edinburgh
Clinical Trials Unit. Participants in the intervention group will be shown how to use blood glucose and blood
pressure monitors and weighing scales which use Bluetooth wireless technology to transmit readings via modem
to a remote server. These participants will be asked to provide at least twice weekly measurements of morning and
evening blood glucose and weekly measurements of weight and blood pressure. Measurements will be checked at
least weekly by practice nurses who will contact the patients to adjust therapy according to guidelines and
reinforce lifestyle advice. Participants in the control group will receive usual care. All participants will receive an
individual education session.
Follow-up: measurements will be performed at practices 9 months after randomization by research nurses blinded
to allocation. The primary outcome measure is HbA1c and secondary outcomes measure are daytime systolic and
diastolic blood pressure, weight and cost per quality-adjusted life year.
Analysis: intention-to-treat analyses will be performed. The sample size of 320 participants allows for 20% drop-out
and has 80% power at 5% significance to detect a 0.5% absolute (6 mmol/mol) fall in HbA1c in the intervention
group. The qualitative study will explore the experiences of patients and professionals using the intervention.
Trial registration: Trial registration number ISRCTN71674628
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The prevalence of diagnosed diabetes is increasing
across the world and, in Scotland, has increased from
3.9% to 4.7% in people of all ages between 2006 and
2011 according to the annual Diabetes Survey [1]. Esti-
mates of total (both diagnosed and undiagnosed) diabetes
from the Association of Public Health Observatories
model for people over 15 years of age in Scotland suggest
that the prevalence will increase from 6.7% in 2010 to
8.6% in 2030 [2]. Annual healthcare costs of a patient with
type 2 diabetes are over six times higher than the costs of
a person without, largely due to the development of
diabetes-related complications. However, control of blood
glucose and blood pressure (as well as management of
dyslipidemia) among people with diabetes reduces compli-
cations and mortality [3-5].
The current medical model for managing diabetes does
not necessarily engage individuals in a self-management
approach, is expensive and often not very effective partly
because therapeutic inertia may result in reluctance to
change treatments. Effective chronic disease management
should not only reduce costs but also improve quality of
care. A study in the US has found that providing
healthcare professionals with current patient information
improved care and reduced costs [6]. Systematic reviews
indicate that engaging patients in self-monitoring and
management can improve clinical outcomes in asthma [7]
but the evidence that self-monitoring alone is beneficial in
people with type 2 diabetes [8] is less clear. This may be
because adherence to both lifestyle advice and prescribed
medication for these groups is poor generally [9] but also
because feedback from clinicians is often infrequent,
potentially adding to patient anxiety in the presence of
abnormal self-monitored readings [10].
As described previously in the protocol for a trial of
telehealthcare among people with chronic obstructive
pulmonary disease from our group [11], several health
service policies support the need to establish the cost-
effectiveness of supported self-monitoring: shifting the
balance of care for people with chronic conditions to
primary care [12,13]; the drive for technological solu-
tions to healthcare problems [14]; and the importance of
expert patients and self-management of long-term con-
ditions [15,16]. While some evidence can be gleaned
from international research into telemetric solutions for
chronic disease management and there are encouraging
results from UK and international pilot studies [17-21],
further research into the cost-effectiveness of these in-
terventions is required, particularly within the National
Health Services in the UK [22]. The Telescot research
program was designed using frameworks for the devel-
opment and evaluation of complex interventions [23,24].
Building on existing literature [17,25,26], and in an itera-
tive process using insights from completed and on-goingexploratory and pilot work [27], we have designed sev-
eral complementary Phase III randomized controlled tri-
als. These will evaluate how telemetry-aided, supervised
self-monitoring affects the management of long-term
conditions in four different contexts (largely asymptomatic
conditions using the example of hypertension; symptom-
atic, potentially unstable and progressive conditions using
the example of chronic obstructive pulmonary disease; an
older, more disabled group with challenging management
targets using the example of hypertension among stroke
survivors; co-morbid conditions using the example of dia-
betes, hypertension and weight management). This paper
describes the protocol for the latter trial in which the aim
is to establish whether supported telemetric monitoring of
glycemic control and blood pressure results in reductions
in glycosylated hemoglobin (HbA1c; the primary outcome
of a measure of long-term glycemic control), and second-
ary outcomes of blood pressure and weight among people
with poorly controlled diabetes compared to a control
group receiving a single education session in addition to
usual care.
Methods/Design
Design/setting/participants/ethical approval
The Telescot diabetes trial is a randomized controlled
trial of supported telemetric monitoring of glycemic
control, blood pressure and weight of 9 months duration
with a primary outcome of HbA1c, a measure of long-
term glycemic control. Secondary outcomes include blood
pressure and weight and will be measured by research
nurses blinded to allocation group. The setting for the trial
is primary care in Lothian, Kent and Borders in the UK.
Participants will have poorly controlled type 2 diabetes
(defined as HbA1c>7.5% (58 mmol/mol)), be over 17 years
of age, have a mobile telephone signal available at their
home and each participant will have given informed
consent. People with very high blood pressure (>210/135
mmHg), who have hypertension or renal disease managed
in secondary care, have had treatment for a cardiac event,
or other life-threatening illness within the past 6 months
or have had major surgery within the last 3 months, are
unable to use self-monitoring equipment, have atrial fibril-
lation that has not been successfully treated or are preg-
nant will be excluded. Approval of the trial, which will be
conducted to comply with the Declaration of Helsinki, has
been obtained from the South East Scotland ethics com-
mittee 2 (reference number: 10/S1102160).
Recruitment
We will recruit socially diverse practices to the trial
using both the Scottish and English Primary Care and
Diabetes Research Networks. We will make use of the
network of practices in Lothian we have established during
a previous blood pressure trial, who are familiar with the
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take part. We will also use the networks and contacts pro-
vided by our grantholders to extend recruitment beyond
Lothian to Kent and Borders. Training for the practices
will be provided by the research team.
Diabetes registers in participating practices will be
searched to identify potential participants with HbA1c>7.5%
(58 mmol/mol). Potentially eligible patients will be sent
the study materials by their general practice with a cover-
ing letter and asked to contact the researcher if they are
interested in participating. Once a patient has indicated
interest in participating they will be invited to a clinic in
their general practitioner’s (GP’s) surgery run by a research
nurse. At the initial appointment the nurse will go through
the study information with the patient, take written in-
formed consent (which will cover consent to have their
eligibility checked as well as their consent to take part in
the trial), check potential eligibility, ask the patient to
complete a short questionnaire on their demographic
characteristics, past and current self-monitoring of blood
pressure and blood glucose, collect a blood sample for
HbA1c and cholesterol measurement, a urine sample for
sodium:creatinine ratio and initiate ambulatory blood
pressure monitoring using the Spacelab Ambulatory Blood
Pressure Monitor (ABPM) [28]. The nurse will also explain
the process for recruitment and potential randomization if
patients are eligible.
All patients will be loaned an ABPM with which they
can monitor their blood pressure for 14 hours. However,
if they wish they can delay collecting ABPM data until
after the result of their HbA1C is available and their eli-
gibility is confirmed. Once the HbA1c result is available,
any ineligible patients will be telephoned to let them
know that they do not need to return for a second ap-
pointment to gather baseline measurements. Patients’
ABPM results will be released to the practice.
Baseline measurements
At their second appointment, prior to randomization,
participants will have the following baseline measure-
ments taken: smoking history, height and weight, and
exhaled carbon monoxide. In addition they will be asked
to complete a range of questionnaires to collect informa-
tion on anxiety/depression [29], quality of life [30], self-
efficacy [31], medication adherence [32], physical activity
[33], exercise tolerance [34], knowledge of managing dia-
betes [35] and ethnic group, based on categories included
in the 2011 Census [36].
Randomization will be carried out remotely at the
Edinburgh Clinical Trials Unit to ensure adequate con-
cealment. We will use minimization with a random elem-
ent based on age (<70 or ≥70 years of age), sex, location
(that is, Lothian, Kent, Glasgow or Borders) use of two or
more diabetes drugs, use of three or more hypertensiondrugs and glucose self-monitoring history in order to
make sure that these factors are distributed equally be-
tween intervention and usual care groups. The allocated
treatment code will be generated by the Edinburgh
Clinical Trials Unit over the internet (with a telephone
back-up option if required). The participant will then be
informed about the arm of the trial to which they have
been assigned and given appropriate information and
demonstration of equipment if allocated to the interven-
tion group. All randomized participants will be included
in the intention-to-treat analysis. All participants, regard-
less of allocation group, will be seen by a healthcare pro-
fessional from the practice trained in the management of
type 2 diabetes who will assess current control, optimize
management in line with Scottish Intercollegiate Guide-
lines Network and National Institute of Health and Clin-
ical Excellence (NICE) guidelines and deliver a one-to-one
standardized education session.
It is not possible to blind clinicians or patients to the
allocation group but baseline data collection will be
undertaken by the research nurses before randomization
takes place. Patients will be requested not to reveal their
allocation to research nurses undertaking follow-up
measurements, although we recognize that inadvertent
references by the patients or in their primary care record
may reveal their allocation. The use of objective out-
comes (HbA1c, ambulatory blood pressure, weight, vali-
dated questionnaires) will also reduce the possibility of
bias. Patients will be asked not to reveal which group
they are in or to return their equipment until the final
monitoring has been carried out. The research nurses
will be asked to record unblinding prior to the final
assessment.
Intervention
Patients in the intervention group will be given blood
pressure and blood glucose monitors and weighing
scales which use Bluetooth to transmit readings via a
(supplied) modem to a remote server. The user may se-
curely access their record on the server at any time (either
at home if they have internet access, or in a library or
other public internet access point). Their GP and practice
nurse will also be able to access this record via the Inter-
net. Users will also receive regular (monthly) feedback
based on their blood pressure and blood glucose over the
past 10 readings which will be sent by post or email
according to the patient’s wishes.
Participants will be trained in use of the equipment
and the demonstration will be backed up by written infor-
mation. The written information pack will also contain
leaflets about initiating or maintaining lifestyle changes
and how long it is likely to be before any lifestyle or medi-
cation change will have an impact on their rolling average
blood pressure or blood glucose. The suggested lifestyle
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diet and increasing physical activity.
The user will also be given contact details for the prac-
tice nurse and encouraged to make contact by email or by
telephoning at specified times if their blood pressure or
blood glucose remains high, to discuss their treatment. In
the event of a very high blood pressure (>220 mmHg) or
very high blood glucose levels (>15 mmol/l) patients will
be asked to repeat the measurements and, if they remain
high, to contact their practice urgently for advice. Patients
recording very low blood glucose (<4 mmol/l) will be ad-
vised to eat or take a glucose drink and, if hypoglycemia
persists, to contact the practice. Practice nurses will be
encouraged to review the readings they are sent about pa-
tients whose blood pressure or blood glucose remains high
or persistently low or who have not checked their blood
pressure or blood glucose within the agreed timeframe on
a weekly basis. Practice nurses may choose to contact the
patient to offer further treatment or support and will be
asked to record such contacts in the normal practice
electronic record. The nurses will also be asked to transfer
the current average blood pressure and blood glucose into
the primary care record.
Patients will be encouraged to check their blood pres-
sure 10 to 20 times over the first seven days to establish a
reliable average and then about 4 times a month if their
average blood pressure is at or below the target of 130
mmHg. If blood pressure is above the target and any
changes to lifestyle or medication are made, the users will
be asked to undertake another more intensive period of
monitoring (10 to 20 readings over seven days) after an
appropriate time (usually 3 to 4 weeks depending on
medication change) in order to establish the impact on the
rolling average blood pressure. The guidance will not be
restrictive as this tool is being provided for patients to
use in order to understand their blood pressure better
and to better manage their own health.
Patients in the intervention group will be asked to pro-
vide at least twice weekly measurements of morning and
evening blood glucose and weekly measurements of morn-
ing weight. These measurements will be automatically
forwarded to the study website and checked at least
weekly by the practice nurse. Patients with high readings
will be highlighted by the software for easy identification.
The nurses will contact the patients by telephone, text or
email to adjust therapy and reinforce lifestyle advice on
the need for more or less intensive monitoring. Antihyper-
tensive drug treatment may be altered every 4 to 6 weeks
until mean blood pressure based on the last 10 readings is
at or below the target of 130 mmHg. Treatment for
diabetes will be altered according to the protocol based on
guidelines every 4 weeks with the aim of maintaining
consecutive fasting blood levels between 4 and 6 mmol/l.
Patients who require the addition of insulin to theirtreatment during the course of the trial will be jointly
managed by the practice nurse and GP along with special-
ist diabetes nurses at the local hospital (if appropriate)
according to local practice, all of whom will have access to
the telemetric data for patients in the intervention group.
Algorithms for glucose and blood pressure management
are given in the appendices.Control group
Patients in the control group will receive leaflets with
lifestyle advice and usual care, that is attending the prac-
tice nurse or GP for appointments as normal. They will
be asked about their use of self-monitoring of blood
pressure and blood glucose at baseline and follow-up.
Patients with uncontrolled blood pressure in our recent
audit saw the nurse or doctor three or four times on
average in 6 months and we would anticipate a similar
number of attendances for patients with both uncon-
trolled glycemia and blood pressure. Patients requiring
insulin during the course of the trial will be managed
jointly as above with specialist diabetes nurse support.
Throughout the trial, patients will be reviewed according
to clinical need by their normal clinical advisors. Clinical
care in both groups for patients in Lothian will be in ac-
cordance with NHS Lothian protocols which are based on
the recommendations of national and international guide-
lines, and in other areas according to NICE guidance.
Therapeutic algorithms for both controls and intervention
will follow guidelines, based upon the NICE guidelines
[37] using a standard stepped treatment program for
blood glucose.Follow-up measurements
Participants will be seen by a researcher/research nurse
blinded to their allocation at their GP practice 9 months
after randomization. The follow-up appointment will
include completion of questionnaires to collect informa-
tion as at baseline, other than ethnicity, blood sample
collection for HbA1c and cholesterol and fitting of the
ABPM. Participants will be asked to return the ABPM
the following day. Use of healthcare resources (number
and duration of hospital admissions, including whether
primary diagnosis was diabetes-related, practice and out-
of-hours consultations, routine reviews for blood pres-
sure or diabetes, prescriptions for antihypertensive and
diabetes drugs and test-strips) and adverse events will be
extracted from the participant’s electronic record by the
researcher or research nurse at the follow-up appoint-
ment. Electronic records will be retrieved and analyzed
for compliance with monitoring. The baseline measures
(excluding height) will be repeated at the end of the 9
month follow-up period.
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Records will be kept of the numbers of practices and
patients that were approached to participate in the study
and the numbers and proportions of practices and pa-
tients that consented or declined to take part. Data from
participating individuals will be entered from question-
naires and paper records by the researcher to a database.
A random 10% sample will be checked for accuracy by
independent trial staff. If we detect systematic errors we
will re-enter all the data. Every attempt will be made to
collect complete data on all of the participants.
Data analysis will be carried out by the Edinburgh
Clinical Trials Unit. Data will be analyzed on an
intention-to-treat basis, that is by allocation group regard-
less of compliance with the intervention. In the primary
analysis we will remove patients with missing outcome
data, but will perform sensitivity analyses to investigate
the effect of this. Binary outcomes will be presented both
as relative and absolute risk reductions. For HbA1c and
blood pressure, and other normally distributed measure-
ments that are taken at baseline and follow-up, adjustment
for baseline measures will be performed using analysis of
covariance. For the primary outcome, subgroup analyses
will be performed based on sex, tertiles of age and socio-
economic status (based on the Scottish Index of Multiple
Deprivation derived from postcode) and tertiles of base-
line HbA1c, home self-monitored systolic blood pressure
and body mass index. These factors may all reasonably be
hypothesized to influence the effect of the intervention.
Subgroup analyses will be performed by adding any inter-
action between these factors and treatment into the
analysis of covariance model and observing whether the fit
of the model is statistically significantly improved. No
interim analysis is planned.
Sample size calculation
There were 4440 people with type 2 diabetes, an HbA1c
of >7.5% and systolic blood pressure of ≥135 mmHg on
the Lothian diabetes register in 2008. This group reflects
approximately 16% of people on the register with type 2
diabetes. Their mean (standard deviation) HbA1c was
8.8% (1.4%) and their mean (standard deviation) systolic
blood pressure was 149 mmHg (13 mmHg).
Using these values, we calculate that a randomized
controlled trial with 125 people completing each arm
with no change in values in the control group at the end
of the trial would have 80% power at 5% significance to
detect a 0.5% absolute fall in HbA1c and a 5 mmHg fall
in systolic blood pressure in the intervention group. In an
earlier trial of telemetric monitoring of blood pressure,
60% of patients on a practice hypertension register agreed
to take part and 82% were retained within the trial [38];
we anticipate similar recruitment and retention rates in
this study. We therefore plan to recruit a total ofapproximately 320 patients to ensure two final group sizes
of 125 people which will provide sufficient power (assum-
ing that up to 20% of people may drop out of the trial).
We anticipate that this will involve recruiting 25 to 30
large general practices to participate in the study.
Health economic analysis
The health economic analyses will assess the cost-
effectiveness of the tele-supported self-monitoring com-
pared to usual care. A cost-utility analysis (incremental
cost per quality-adjusted life year) will be performed. The
perspective will be the NHS. The benefits will include
health outcomes measured in terms of quality-adjusted life
years which will be derived from the responses to the EQ-
5D [30]. Health service (GP/nurse consultations, tele-
phone consultations, home visits, accident and emergency
attendances, out-patient consultations, hospitalizations)
and drug use over the trial period will be extracted from
practice records to check the validity of self-reporting.
Nurses will be asked how much time they use checking
the website and on the telephone to patients. The costs of
the tele-monitoring equipment and the set-up and support
costs will be estimated using expert judgment. Resource
use estimates will be combined with unit costs obtained
from standard sources such as the Personal Social Services
Research Unit. The results of the economic evaluation will
be presented as an incremental cost-effectiveness ratio
(cost-utility analysis). The evaluation will include both de-
terministic and probabilistic sensitivity analysis. Modeling
of longer term costs and benefits will be explored using
estimates from published studies including UKPDS [39].
Advice on the health economics analysis is being provided
by Dr Marjon van der Pol from the Health Economics Re-
search Unit at the University of Aberdeen and Andrew
Stoddart from the Health Services Research Unit at the
University of Edinburgh.
Qualitative study
Participants
A sub-sample of participants in the randomized con-
trolled trial will be recruited to the nested qualitative
study. Up to 20 participants from the intervention group
will be recruited for semi-structured interviews plus a
further 10 to 12 for two focus groups. The purpose of
the focus groups will be to allow the group to explore
shared ideas and experiences relating to type 2 diabetes
and hypertension and their experiences in managing it.
The interviews with individuals will cover similar sub-
jects but will allow private discussion of issues such as
not using medication in the prescribed way (which
people may not be willing to discuss in a public situ-
ation). A maximum variation sample in relation to age,
social class, ethnicity (if ethnicity varies sufficiently be-
tween participants) and severity of type 2 diabetes and
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sought.
Healthcare professionals
Up to 20 professionals participating in the trial will be
interviewed (face-to-face or by telephone according to
the preference of the clinician). This will include the
specialist diabetes nurses providing the support services,
long-term condition nurses, and representatives of pri-
mary and secondary care services.
Topic guides
The initial guide for semi-structured interviews with
patients will be based on the themes identified from the
literature and the on-going studies, but the guide will be
reviewed and refined iteratively as data are gathered and
analyzed and new themes arise. Participants will there-
fore be encouraged to give their views on the usefulness
of the systems in general and then tell their own story
about managing their own long-term conditions and the
impact of the systems.
Interviews with professionals will seek to investigate
perceptions of the benefits (or otherwise) of the inter-
vention, experiences of implementing and maintaining it
and the barriers and facilitators they have experienced.
Analysis
The interviews and focus groups will be fully transcribed.
The Framework method will be used to classify and
organize data according to key themes, concepts and
emergent categories [40]. Data will be analyzed from the
theoretical perspective of the diffusion of innovations lit-
erature and the behavior change literature, underpinned
by social learning theory, which emphasize the importance
of people’s perceptions in understanding their behavior in
relation to an innovation [41-45]. Initial coding will be car-
ried out by the qualitative researcher with reference to the
transcripts and voice recordings and the analysis recorded
using NVivo 7 QSR international Pty Ltd’ 2nd Floor, 651
Doncaster Road, Doncaster, Victoria 3108 Australia Con-
stant comparison (checking experiences against those of
others in the sample) will ensure that the thematic analysis
represents all perspectives and negative cases will be
sought. The analysis will then be reviewed by the wider
research team to aid interpretation. Validity checking of
the analysis will include recoding of some interviews by an
independent researcher and coding review of some of the
data by a patient reference group.
Discussion
The proposed trial will provide additional information
on the cost-effectiveness and feasibility of supported
telemetric monitoring of two common, chronic condi-
tions, diabetes and hypertension, whose prevalence isexpected to continue increasing across the world. Limi-
tations of the trial include the potential for unblinding
of research nurses undertaking follow-up measurements
to allocated group and the inability to identify whether
the intervention may be more effective in patient sub-
groups, for example people with newly diagnosed dia-
betes or who may shortly require insulin treatment. In
addition the assumption that outcome measures among
the comparison group will remain unchanged may not
hold which will either strengthen or weaken the power
of the study depending on the direction in which
change occurs. The study design also precludes investi-
gation of whether effectiveness of the intervention
would be influenced by separate monitoring of blood
pressure and glycemic control in different groups as this
would require a factorial design. The standard limita-
tion of all health services research that it is difficult to
generalize the findings regarding feasibility to other set-
tings also applies to this work, but the effectiveness of
the intervention may have wider application to other
populations.
Trial status
Ongoing. Recruitment started in August 2011 and follow-
up is expected to be complete by April 2014.
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